Fluorofenidone attenuates diabetic nephropathy and kidney fibrosis in db/db mice

Pharmacology

Volumn 88, Issue 1-2, 2011, Pages 88-99

  Wang, Ling Hao ^a   Liu, Ji Shi ^a   Ning, Wang Bin ^a   Yuan, Qiong Jing ^a   Zhang, Fang Fang ^a   Peng, Zhang Zhe ^a   Lu, Miao Miao ^a   Luo, Ren Na ^a   Fu, Xiao ^a   Hu, Gao Yun ^b   Wang, Zhao He ^d   Tao, Li Jian ^a,c  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b Faculty of Pharmaceutical Sciences   (China)

^c CENTRAL SOUTH UNIVERSITY   (China)

^d Sunshine Lake Pharma Co Ltd   (China)

Author keywords

db db mouse; Diabetic nephropathy; Fluorofenidone; Mesangial cell; Transforming growth factor 1

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN TYPE 1; COLLAGEN TYPE 1 ALPHA 1; COLLAGEN TYPE 1 ALPHA 4; DIPYRONE; FIBRONECTIN; FLUOROFENIDONE; GLUCOSE; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ALBUMINURIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DOSE RESPONSE; DRUG MECHANISM; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; KIDNEY CORTEX; KIDNEY FIBROSIS; KIDNEY HYPERTROPHY; MALE; MESANGIUM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; WESTERN BLOTTING;

ALBUMINS; ANIMALS; BLOOD GLUCOSE; CELL CULTURE TECHNIQUES; COLLAGEN; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; EXTRACELLULAR MATRIX; FIBRONECTINS; FIBROSIS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; KIDNEY; KIDNEY CORTEX; KIDNEY DISEASES; MALE; MICE; MICE, KNOCKOUT; PYRIDONES; TRANSFORMING GROWTH FACTOR BETA1;

EID: 80051577424     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000329419     Document Type: Article

References (45)

1. Ning G, Hong J, Bi Y, et al: Progress in diabetes research in China. J Diabetes 2009; 1: 163-172.
2. Kaul K, Hodgkinson A, Tarr JM, Kohner EM, Chibber R: Is inflammation a common retinal-renal-nerve pathogenic link in diabetes? Curr Diabetes Rev 2010; 6: 294-303.
3. Schellhase KG, Koepsell TD, Weiss NS: Glycemic control and the risk of multiple microvascular diabetic complications. Fam Med 2005; 37: 125-130. (Pubitemid 40204469)
4. Mehdi UF, Adams-Huet B, Raskin P, et al: Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol 2009; 20: 2641-2650.
5. Choudhury D, Tuncel M, Levi M: Diabetic nephropathy, a multifaceted target of new therapies. Discov Med 2010; 10: 406-415.
6. Mason RM, Wahab NA: Extracellular matrix metabolism in diabetic nephropathy. J Am Soc Nephrol 2003; 14: 1358-1373. (Pubitemid 36519197)
7. Berrou J, Tostivint I, Verrecchia F, et al: Advanced glycation end products regulate extracellular matrix protein and protease expression by human glomerular mesangial cells. Int J Mol Med 2009; 23: 513-520.
8. Kanwar YS, Wada J, Sun L, et al: Diabetic nephropathy: Mechanisms of renal disease progression. Exp Biol Med (Maywood) 2008; 233: 4-11.
9. Chiarelli F, Gaspari S, Marcovecchio ML: Role of growth factors in diabetic kidney disease. Horm Metab Res 2009; 41: 585-593.
10. Hayashida T, Schnaper HW: High ambient glucose enhances sensitivity to TGF-1 via extracellular signal-regulated kinase and protein kinase C activities in human mesangial cells. J Am Soc Nephrol 2004; 15: 2032-2041. (Pubitemid 39031342)
11. Luo P, Zhou Y, Chang HH, et al: Glomerular 20-HETE, EETs, and TGF-1 in diabetic nephropathy. Am J Physiol Renal Physiol 2009; 296: 556-563.
12. Hills CE, Squires PE: TGF-1 -induced epithelial-to-mesenchymal transition and therapeutic intervention in diabetic nephropathy. Am J Nephrol 2010; 31: 68-74.
13. Baricos WH, Cortez SL, Deboisblanc M, et al: Transforming growth factor-is a potent inhibitor of extracellular matrix degradation by cultured human mesangial cells. J Am Soc Nephrol 1999; 10: 790-795. (Pubitemid 29149529)
14. Chen S, Iglesias-de la Cruz MC, Jim B, et al: Reversibility of established diabetic glomerulopathy by anti-TGF-antibodies in db/db mice. Biochem Biophys Res Commun 2003; 300: 16-22. (Pubitemid 36042924)
15. Xia L, Wang H, Munk S, et al: High glu -cose activates PKC-and NADPH oxidase through autocrine TGF-1 signaling in mesangial cells. Am J Physiol Renal Physiol 2008; 295:F1705-F1714.
16. Sugaru E, Nakagawa T, Ono-Kishino M, et al: SMP-534 ameliorates progression of glomerular fibrosis and urinary albumin in diabetic db/db mice. Am J Physiol Renal Physiol 2006; 290:F813-F820. (Pubitemid 43724941)
17. Petersen M, Thorikay M, Deckers M, et al: Oral administration of GW788388, an inhibitor of TGF-type I and II receptor kinases, decreases renal fibrosis. Kidney Int 2008; 73: 705-715. (Pubitemid 351323246)
18. Li J, Kang SW, Kim JL, et al: Isoliquiritigenin entails blockade of TGF-1 -SMAD signaling for retarding high glucose-induced mesangial matrix accumulation. J Agric Food Chem 2010; 58: 3205-3212.
19. Turgut F, Bolton WK: Potential new therapeutic agents for diabetic kidney disease. Am J Kidney Dis 2010; 55: 928-940.
20. Shimizu T, Fukagawa M, Kuroda T, et al: Pirfenidone prevents collagen accumulation in the remnant kidney in rats with partial nephrectomy. Kidney Int Suppl 1997; 63: 239-243.
21. Miric G, Dallemagne C, Endre Z, et al: Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocindiabetic rats. Br J Pharmacol 2001; 133: 687-694. (Pubitemid 32642874)
22. Brook NR, Waller JR, Bicknell GR, et al: The experimental agent pirfenidone reduces profibrotic gene expression in a model of tacrolimus-induced nephrotoxicity. J Surg Res 2005; 125: 137-143. (Pubitemid 40602384)
23. RamachandraRao SP, Zhu Y, Ravasi T, et al: Pirfenidone is renoprotective in diabetic kidney disease. J Am Soc Nephrol 2009; 20: 1765-1775.
24. Cho ME, Smith DC, Branton MH, et al: Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2007; 2: 906-913.
25. Wang L, Hu GY, Shen H, et al: Fluorofenidone inhibits TGF-1 -induced CTGF via MAPK pathways in mouse mesangial cells. Pharmazie 2009; 64: 680-684.
26. Peng ZZ, Hu GY, Shen H, et al: Fluorofenidone attenuates collagen I and transforming growth factor-1 expression through a nicotinamide adenine dinucleotide phosphate oxidase-dependent way in NRK-52E cells. Nephrology (Carlton) 2009; 14: 565-572.
27. Chen H, Charlat O, Tartaglia LA, et al: Evidence that the diabetes gene encodes the leptin receptor: Identification of a mutation in the leptin receptor gene in db/db mice. Cell 1996; 84: 491-495. (Pubitemid 26060722)
28. Hummel KP, Dickie MM, Coleman DL: Diabetes, a new mutation in the mouse. Science 1966; 153: 1127-1128.
29. Sharma K, McCue P, Dunn SR: Diabetic kidney disease in the db/db mouse. Am J Physiol Renal Physiol 2003; 284:F1138-F1144. (Pubitemid 36578440)
30. Chin M, Isono M, Isshiki K, et al: Estrogen and raloxifene, a selective estrogen receptor modulator, ameliorate renal damage in db/db mice. Am J Pathol 2005; 166: 1629-1636. (Pubitemid 40734386)
31. Baba M, Wada J, Eguchi J, et al: Galectin-9 inhibits glomerular hypertrophy in db/db diabetic mice via cell-cycle dependent mechanisms. J Am Soc Nephrol 2005; 16: 3222-3234. (Pubitemid 46179328)
32. Flyvbjerg A, Denner L, Schrijvers BF, et al: Long-term renal effects of a neutralizing RAGE antibody in obese type 2 diabetic mice. Diabetes 2004; 53: 166-172. (Pubitemid 38044711)
33. Cha DR, Zhang XY, Zhang YH, et al: Peroxisome proliferator-activated receptor dual agonist tesaglitazar attenuates diabetic nephropathy in db/db mice. Diabetes 2007; 56: 2036-2045.
34. Sugaru E, Nakagawa T, Ono-Kishino M, et al: SMP-534 ameliorates progression of glomerular fibrosis and urinary albumin in diabetic db/db mice. Am J Physiol Renal Physiol 2006; 290: 813-820.
35. Hong SW, Isono M, Chen S, et al: Increased glomerular and tubular expression of transforming growth factor-1 , its type II receptor, and activation of the Smad signaling pathway in the db/db mouse. Am J Pathol 2001; 158: 1653-1663. (Pubitemid 32422930)
36. Cao W, He L, Liu W, Huang Z, et al: Determination of AKF-PD in whole blood of rat by HPLC-UV. J Chromatogr B Analyt Technol Biomed Life Sci 2006; 833: 257-259.
37. RamachandraRao SP, Zhu Y, Ravasi T, et al: Pirfenidone is renoprotective in diabetic kidney disease. J Am Soc Nephrol 2009; 20: 1765-1775.
38. Mason RM, Wahab NA. Extracellular matrix metabolism in diabetic nephropathy. J Am Soc Nephrol 2003; 14: 1358-1373. (Pubitemid 36519197)
39. Yano N, Suzuki D, Endoh M, et al: High ambient glucose induces angiotensin-independent AT-1 receptor activation, leading to increases in proliferation and extracellular matrix accumulation in MES-13 mesangial cells. Biochem J 2009; 423: 129-143.
40. Brew K, Dinakarpandian D, Nagase H: Tissue inhibitors of metalloproteinases: Evolution, structure and function. Biochim Biophys Acta 2000; 1477: 267-283. (Pubitemid 30119906)
41. Hong SW, Isono M, Chen S, et al: Increased glomerular and tubular expression of transforming growth factor-1 , its type II receptor, and activation of the Smad signaling pathway in the db/db mouse. Am J Pathol 2001; 158: 1653-1663. (Pubitemid 32422930)
42. Ziyadeh FN, Hoffman BB, Han DC, et al: Long-term prevention of renal insufficiency, excess matrix gene expression and glomerular mesangial matrix expression by treatment with monoclonal anti-TGF-antibody in db/db diabetic mice. Proc Natl Acad Sci USA 2000; 97: 8015-8020. (Pubitemid 30460765)
43. Fukuda N, Tahira Y, Matsuda H, et al: Transforming growth factor-as a treatment target in renal diseases. J Nephrol 2009; 22: 708-715.
44. Lee S, Kim W, Moon SO, et al: Renoprotective effect of COMP-angiopoietin-1 in db/db mice with type 2 diabetes. Nephrol Dial Transplant 2007; 22: 396-408. (Pubitemid 46189882)
45. Haneda M, Koya D, Isono M, et al: Overview of glucose signaling in mesangial cells in diabetic nephropathy. J Am Soc Nephrol 2003; 14: 1374-1382. (Pubitemid 36514677)